1. Scrip
  2. >>Business
  3. >>Stock Watch

Stock Watch: Spanners In The Works For Q4 Results

Missed Estimates And Accounting Regulations Could Foul The Pitch

 
• By Andy Smith

While the implications of the US Inflation Reduction Act are the focus of the sector’s concern this year, another regulatory development will impact earnings sooner.

Stock Watch Image, Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

The fourth-quarter and full-year 2022 earnings season for life science companies is just around the corner. This quarter in particular is usually something to look forward to because sales are typically better in the final quarter of the year. Companies might also incorporate the boost in revenues from early January’s list price increases into their full-year financial guidance as they report fourth-quarter sales that benefited from drug wholesalers and big pharmacy groups over-ordering in the fourth quarter in anticipation of those price hikes – just as they did at the start of the pandemic when supply chain disruption was anticipated.

That was in the days when list prices meant more than just determining the out-of-pocket cost for those privately and...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Stock Watch

More from Business

Biogen Edges Closer To Growth On Strong Q2

 
• By Jessica Merrill

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.

Amvuttra Makes Strong ATTR-CM Showing As Alnylam Prepares For Global Launches

 
• By Alaric DeArment

In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.

Argenx Powers Ahead With Vyvgart’s Prefilled Syringe Launch

 
• By Andrew McConaghie

The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.